U.S. Autoimmune Disease Therapeutics Market Insight
U.S. Autoimmune Disease Therapeutics market size is growing at a 4.6% CAGR, driven by the rising demand for personalized shopping, AI-driven recommendations, automated customer support, fraud detection
U.S. Autoimmune Disease Therapeutics Market Insights Forecasts to 2035
- The U.S. Autoimmune Disease Therapeutics Market Size Was Estimated at USD 62.78 Billion in 2025.
- The Market Size is Expected to Grow at a CAGR of around 4.6% from 2025 to 2035.
- The U.S. Autoimmune Disease Therapeutics Market Size is Expected to Reach USD 98.41 Billion by 2035.
Notable Insights for U.S. Autoimmune Disease Therapeutics Market
- By drug class, biologics dominated the market with over 55% share in 2025, driven by widespread adoption of monoclonal antibodies and targeted immunotherapies for conditions such as rheumatoid arthritis and psoriasis.
- According to Centers for Disease Control and Prevention, more than 50 million Americans are affected by autoimmune diseases, significantly driving demand for long-term therapeutic treatments and specialty drugs.
- Data from National Institutes of Health indicates that autoimmune diseases are among the top causes of chronic illness in the U.S., supporting increased federal funding and clinical research initiatives in immunology.
- Government data indicates that major healthcare employment concentration exists in pharmaceutical manufacturing, biotechnology research, and specialty care services, demonstrating strong cross-industry integration supporting autoimmune disease therapeutics development and delivery.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the U.S. Autoimmune Disease Therapeutics market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in U.S. Autoimmune Disease Therapeutics Market
- AbbVie Inc.
- Johnson & Johnson
- Pfizer Inc.
- Amgen Inc.
- Bristol Myers Squibb
- Eli Lilly and Company
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Sanofi
- Others
Recent Developments:
• UCB announced a $2.2 billion acquisition of Candid Therapeutics (2026) to strengthen its autoimmune pipeline with next-generation T-cell engager biologics targeting immune-mediated diseases.
• The U.S. Food and Drug Administration proposed withdrawing Amgen’s autoimmune drug Tavneos due to safety concerns and insufficient efficacy data, signaling stricter regulatory scrutiny in rare autoimmune therapies.
• Amgen reported Q1 2026 revenue growth, but faced setbacks in its autoimmune portfolio following regulatory challenges to Tavneos, highlighting risk exposure in biologics commercialization.
• Intellia Therapeutics reported 87% reduction in disease attacks in late-stage trials of a gene-editing therapy for hereditary angioedema, indicating breakthrough innovation in autoimmune-related treatment approaches.
Market Segmentation:
U.S. Autoimmune Disease Therapeutics Market, By Drug Class
- Rheumatoid Arthritis
- Psoriasis
- Multiple Sclerosis
- Inflammatory Bowel Disease (Crohn’s Disease & Ulcerative Colitis)
- Systemic Lupus Erythematosus
- Others (Type 1 Diabetes, Ankylosing Spondylitis)
U.S. Autoimmune Disease Therapeutics Market, By Route of Administration
- Injectable
- Oral
- Intravenous
U.S. Autoimmune Disease Therapeutics Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
U.S. Autoimmune Disease Therapeutics Market, By End Use
- Hospitals
- Specialty Clinics
- Homecare Settings
Expert Views:
Experts highlight that the U.S. autoimmune disease therapeutics market is transitioning into a core revenue-driving segment for pharmaceutical companies, rather than a niche specialty area. The rapid shift toward biologics and targeted immunotherapies is becoming standard, driven by higher efficacy and long-term disease management benefits. Industry analysts emphasize that monoclonal antibodies and interleukin inhibitors deliver the highest commercial returns due to strong clinical outcomes and premium pricing models. At the same time, the rise of biosimilars is improving treatment accessibility while intensifying pricing competition across major drug classes.